Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Satellos Bioscience Inc. is a biotechnology firm focused on developing regenerative therapies for muscle diseases, leveraging its proprietary technology platform to target muscle regeneration. The company's unique approach to muscle repair and regeneration positions it well within the growing market for rare disease treatments, particularly in North America and Europe.
Satellos primarily generates revenue through research grants and partnerships with larger pharmaceutical companies, focusing on the development of therapies for muscle-related diseases. The company has a strong intellectual property portfolio that provides a competitive edge, allowing it to negotiate favorable terms in collaborations.
Progress in clinical trials for muscle regeneration therapies
Partnership announcements with larger pharmaceutical companies
Regulatory approvals or advancements in drug development
Market sentiment towards biotechnology sector developments
Regulatory changes that could impact drug approval processes
Technological disruptions in the biotechnology space
Emergence of new competitors with similar regenerative therapies
Potential for larger pharmaceutical companies to develop in-house solutions
High cash burn rate due to ongoing R&D without revenue generation
Dependency on external funding sources for operational sustainability
low - The biotechnology sector is less sensitive to economic cycles as demand for healthcare and innovative treatments remains relatively stable regardless of economic conditions.
Moderate - Rising interest rates can increase the cost of capital for biotech firms, potentially impacting funding for R&D and clinical trials.
minimal - The company has no debt, which reduces its exposure to credit market fluctuations.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
high - The stock has historically shown significant price volatility due to the binary nature of clinical trial outcomes.